Mary E. Rinella

46.0k total citations · 18 hit papers
133 papers, 21.5k citations indexed

About

Mary E. Rinella is a scholar working on Epidemiology, Hepatology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Mary E. Rinella has authored 133 papers receiving a total of 21.5k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Epidemiology, 68 papers in Hepatology and 42 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Mary E. Rinella's work include Liver Disease Diagnosis and Treatment (121 papers), Liver Disease and Transplantation (45 papers) and Diet, Metabolism, and Disease (38 papers). Mary E. Rinella is often cited by papers focused on Liver Disease Diagnosis and Treatment (121 papers), Liver Disease and Transplantation (45 papers) and Diet, Metabolism, and Disease (38 papers). Mary E. Rinella collaborates with scholars based in United States, United Kingdom and France. Mary E. Rinella's co-authors include Arun J. Sanyal, Brent A. Neuschwander‐Tetri, Scott L. Friedman, Stephen A. Harrison, Zobair M. Younossi, Elizabeth M. Brunt, Vincent Wai‐Sun Wong, Kenneth Cusi, Michael Charlton and Elizabeth E. Powell and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Mary E. Rinella

126 papers receiving 21.2k citations

Hit Papers

The diagnosis and management of nonalcoholic fatty liver ... 2015 2026 2018 2022 2017 2018 2015 2021 2023 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
    2017 5.2k citations Naga Chalasani, Zobair M. Younossi et al. Hepatology profile →
  2. Mechanisms of NAFLD development and therapeutic strategies
    2018 3.0k citations Brent A. Neuschwander‐Tetri, Mary E. Rinella et al. profile →
  3. Nonalcoholic Fatty Liver Disease
    2015 1.8k citations Mary E. Rinella profile →
  4. Non-alcoholic fatty liver disease
    2021 1.8k citations Mary E. Rinella et al. profile →
  5. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease
    2023 1.2k citations Mary E. Rinella, Brent A. Neuschwander‐Tetri et al. Hepatology profile →
  6. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease
    2020 864 citations Mary E. Rinella et al. profile →
  7. Nonalcoholic fatty liver disease
    2015 630 citations Elizabeth M. Brunt, Silvia Sookoian et al. profile →
  8. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings
    2022 592 citations Kenneth Cusi, Rita Basu et al. profile →
  9. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    2018 344 citations Stephen A. Harrison, Mary E. Rinella et al. profile →
  10. From NAFLD to MAFLD: Implications of a Premature Change in Terminology
    2020 277 citations Zobair M. Younossi, Mary E. Rinella et al. Hepatology profile →
  11. Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature
    2023 267 citations Jeffrey V. Lazarus, Philip N. Newsome et al. Hepatology profile →
  12. TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a Trial
    2021 163 citations Rohit Loomba, Stephen A. Harrison et al. profile →
  13. Metabolic dysfunction–associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease
    2023 144 citations Fasiha Kanwal, Brent A. Neuschwander‐Tetri et al. Hepatology profile →
  14. From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease
    2023 91 citations Mary E. Rinella, Silvia Sookoian Journal of Lipid Research profile →
  15. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study
    2024 75 citations Emmanuel Tsochatzis, Mary E. Rinella et al. profile →
  16. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis
    2024 55 citations Mazen Noureddin, Michael Charlton et al. Clinical Gastroenterology and Hepatology profile →
  17. Metabolic dysfunction-associated steatotic liver disease in adults
    2025 53 citations Mary E. Rinella, Jeffrey V. Lazarus et al. profile →
  18. Efruxifermin in Compensated Liver Cirrhosis Caused by MASH
    2025 19 citations Mazen Noureddin, Mary E. Rinella et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mary E. Rinella United States 50 18.5k 7.7k 7.4k 4.0k 3.2k 133 21.5k
Quentin M. Anstee United Kingdom 73 19.7k 1.1× 7.9k 1.0× 8.9k 1.2× 4.0k 1.0× 3.1k 1.0× 254 23.9k
Leon A. Adams Australia 62 18.9k 1.0× 7.9k 1.0× 9.1k 1.2× 2.9k 0.7× 3.1k 1.0× 202 22.9k
Michael Charlton United States 69 19.5k 1.1× 6.2k 0.8× 12.9k 1.7× 3.1k 0.8× 5.4k 1.7× 250 25.3k
Melissa J. Contos United States 36 15.9k 0.9× 6.0k 0.8× 7.3k 1.0× 3.3k 0.8× 3.0k 0.9× 58 18.5k
Geoffrey C. Farrell Australia 76 19.9k 1.1× 6.9k 0.9× 10.0k 1.3× 4.7k 1.2× 3.7k 1.2× 213 26.1k
Matthew M. Yeh United States 51 13.4k 0.7× 4.5k 0.6× 5.9k 0.8× 3.5k 0.9× 3.0k 0.9× 129 17.2k
Brent A. Neuschwander‐Tetri United States 67 25.1k 1.4× 11.3k 1.5× 10.2k 1.4× 5.6k 1.4× 5.0k 1.6× 188 30.8k
Christopher P. Day United Kingdom 86 23.0k 1.2× 9.9k 1.3× 10.2k 1.4× 4.1k 1.0× 3.7k 1.1× 186 31.1k
Paul Angulo United States 72 22.1k 1.2× 9.3k 1.2× 11.8k 1.6× 2.7k 0.7× 5.9k 1.8× 155 26.6k
Luca Valenti Italy 70 11.9k 0.6× 5.4k 0.7× 4.1k 0.5× 2.5k 0.6× 2.2k 0.7× 367 16.8k

Countries citing papers authored by Mary E. Rinella

Since Specialization
Citations

This map shows the geographic impact of Mary E. Rinella's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary E. Rinella with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary E. Rinella more than expected).

Fields of papers citing papers by Mary E. Rinella

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary E. Rinella. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary E. Rinella. The network helps show where Mary E. Rinella may publish in the future.

Co-authorship network of co-authors of Mary E. Rinella

This figure shows the co-authorship network connecting the top 25 collaborators of Mary E. Rinella. A scholar is included among the top collaborators of Mary E. Rinella based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary E. Rinella. Mary E. Rinella is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Tsutsumi, Tsubasa, Michael Charlton, Vanessa M. Oddo, et al.. (2025). Aspirin Use and Mediterranean Diet Adherence as Factors Associated With Overall Mortality in Patients With MASLD in NHANES. Hepatology Research. 56(3). 330–338.
3.
Charlton, Michael & Mary E. Rinella. (2025). Liver Transplantation. Clinics in Liver Disease. 29(2). 157–163. 1 indexed citations
4.
Castro‐Narro, Graciela & Mary E. Rinella. (2024). La nueva nomenclatura de esteatosis hepática. ¡No más NAFLD!. Revista de Gastroenterología de México. 89(2). 312–313.
5.
Simon, Tracey G., et al.. (2023). Extrahepatic Outcomes of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease. 27(2). 251–273. 6 indexed citations
6.
Sanyal, Arun J., Rohit Loomba, Quentin M. Anstee, et al.. (2023). Utility of pathologist panels for achieving consensus in NASH histologic scoring in clinical trials: Data from a phase 3 study. Hepatology Communications. 8(1). 7 indexed citations
7.
Lazarus, Jeffrey V., Philip N. Newsome, Sven Francque, et al.. (2023). Reply: A multi-society Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 79(3). E93–E94. 267 indexed citations breakdown →
8.
Nadolsky, Karl, et al.. (2023). Nonalcoholic steatohepatitis diagnosis and treatment from the perspective of patients and primary care physicians: a cross-sectional survey. Annals of Medicine. 55(1). 2211349–2211349. 5 indexed citations
9.
Rinella, Mary E. & Silvia Sookoian. (2023). From NAFLD to MASLD: updated naming and diagnosis criteria for fatty liver disease. Journal of Lipid Research. 65(1). 100485–100485. 91 indexed citations breakdown →
10.
Lazarus, Jeffrey V., Henry E. Mark, Massimo Colombo, et al.. (2021). A sustainable development goal framework to guide multisectoral action on NAFLD through a societal approach. Alimentary Pharmacology & Therapeutics. 55(2). 234–243. 8 indexed citations
11.
Kanwal, Fasiha, Jay H. Shubrook, Zobair M. Younossi, et al.. (2021). Preparing for the NASH epidemic: A call to action. Obesity. 29(9). 1401–1412. 11 indexed citations
12.
Ratziu, Vlad, Mary E. Rinella, Brent A. Neuschwander‐Tetri, et al.. (2021). EDP-305 in patients with NASH: A phase II double-blind placebo-controlled dose-ranging study. Journal of Hepatology. 76(3). 506–517. 87 indexed citations
13.
Rinella, Mary E., Jean‐François Dufour, Quentin M. Anstee, et al.. (2021). Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study. Journal of Hepatology. 76(3). 536–548. 122 indexed citations
14.
Younossi, Zobair M., Maria Stepanova, Fatema Nader, et al.. (2021). Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis. Clinical Gastroenterology and Hepatology. 20(9). 2050–2058.e12. 77 indexed citations
15.
Younossi, Zobair M., Mary E. Rinella, Arun J. Sanyal, et al.. (2020). From NAFLD to MAFLD: Implications of a Premature Change in Terminology. Hepatology. 73(3). 1194–1198. 277 indexed citations breakdown →
16.
Brunt, Elizabeth M., David E. Kleiner, Danielle Carpenter, et al.. (2020). NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology. 73(5). 2028–2038. 99 indexed citations
17.
Younossi, Zobair M., Kathleen E. Corey, Naim Alkhouri, et al.. (2020). Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices. Alimentary Pharmacology & Therapeutics. 52(3). 513–526. 62 indexed citations
18.
Siddiqui, Mohammad, Samarth Patel, Chandra Bhati, et al.. (2019). Range of Normal Serum Aminotransferase Levels in Liver Transplant Recipients. Transplantation Proceedings. 51(6). 1895–1901. 9 indexed citations
19.
Chalasani, Naga, Raj Vuppalanchi, Mary E. Rinella, et al.. (2018). Randomised clinical trial: a leucine-metformin-sildenafil combination (NS-0200) vs placebo in patients with non-alcoholic fatty liver disease. eScholarship (California Digital Library). 1 indexed citations
20.
Chalasani, Naga, Zobair M. Younossi, Joel E. Lavine, et al.. (2017). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 67(1). 328–357. 5150 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Quentin M. Anstee Breakdown of academic impact, for papers by Leon A. Adams Breakdown of academic impact, for papers by Michael Charlton Breakdown of academic impact, for papers by Melissa J. Contos Breakdown of academic impact, for papers by Geoffrey C. Farrell Breakdown of academic impact, for papers by Matthew M. Yeh Breakdown of academic impact, for papers by Brent A. Neuschwander‐Tetri Breakdown of academic impact, for papers by Christopher P. Day Breakdown of academic impact, for papers by Paul Angulo Breakdown of academic impact, for papers by Luca Valenti
Rankless by CCL
2026